TCT-627 Left Ventricular Mass Regression After Transcatheter Or Surgical Aortic Valve Replacement: Importance Of Stroke Volume And The Left Ventricular Mass Formula  by Oh, Jae K. et al.
B256 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5implantation between January 2013 and March 2015, including SA-
PIEN XT (Jan 2013-September 2014) and SAPIEN 3 (October 2014-
March 2015). All patients presented severe aortic stenosis who were
refused for conventional surgery. Procedure success, clinical out-
comes and peri-procedural complications were prospectively assessed
according to the Valve Academic Research Consortium (VARC)-2
criteria.
RESULTS N¼142 consecutive patients who underwent TAVR using
SAPIEN device were included in the study (n¼76 SAPIEN XT and n¼66
SAPIEN 3). There was no difference between groups regarding age,
Euroscore, gender, previous medical history and left ventricle ejection
fraction. However, SAPIEN 3 patients had a higher prevalence of pe-
ripheral arterial disease (65.2 vs. 36.8%, p¼0.001) and ilio-femoral axis
calciﬁcations on scanner (47.9 vs; 26.5 %, p¼0.008) than the others.
Moreover, SAPIEN 3 patients had a smaller aortic valve area than
SAPIEN-XT subjects (0.670.9 vs 0.76  0.14 cm2/m2, p¼0.007), yet
there was no signiﬁcant difference in aortic annulus diameter (254.5
vs 23.82 mm, p¼ns). TAVR was performed through transfemoral
access in 96% in both groups. Device implantation success rate was
higher (100% vs. 90%, p¼0.002) in the SAPIEN 3 than in the SAPIEN-
XT group .The prevalence of moderate to severe paravalvular leak was
lower in SAPIEN 3 than in SAPIEN-XT patients (0% vs 9.2%, p¼0.01).
We observed fewer hemorrhagic events in the SAPIEN 3 group than in
the other, as assessed by the lower incidence of life-
threatening þmajor bleeding events (0% vs 9.2%, p¼0.01). There was
no difference regarding the 30-days rate of MACCE (major adverse
cardiovascular & cerebrovascular events) between patients, including
no difference in terms of death (3% vs. 5%), stroke (3% vs. 2.6%) and
major vascular complications (6% vs. 13.1%). Finally, the rate of per-
manent pacemaker implantation were comparable in both groups
(10.6 vs. 14.5%, p¼0.49).
CONCLUSIONS The use Edwards SAPIEN 3 allows TAVR in patients
with more severe peripheral artery disease. Moreover, this device
provides excellent short-term outcome and lower rates of para-
valvular regurgitations compared to the previous generation SAPIEN-
XT valve.
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BACKGROUND Prospective randomized trials have demonstrated
that transcatheter aortic valve replacement (TAVR) is an effective
alternative to surgical aortic valve replacement (SAVR) for patients
with severe aortic stenosis at increased surgical risk, but reasons why
left ventricular (LV) mass regresses more rapidly and to a greater
extent after SAVR than TAVR despite a higher AV gradient after SAVR
is unknown. We sought to determine why LV mass regression is
greater after SAVR.
METHODS Baseline and serial echocardiography studies of patients
randomized to SAVR with a bioprosthetic valve vs TAVR with a self-
expanding CoreValve were analyzed by an Echo Core Lab blinded toTable. Echocardiographic Parameters by Treatment Over Time
Baseline Discharge
TAVR SAVR TAVR SAVR TA
LVEDD (cm) 4.97  0.63 (347) 5.01  0.64 (311) 4.91  0.64 (303) 4.81  0.65 (225) 4.99  0
IVST (mm) 11.97  2.35 (341) 12.00  2.07 (309) 12.26  2.41 (295) 11.99  1.94 (219) 11.79  2
PWT (mm) 11.19  1.98 (338) 11.24  1.95 (311) 11.39  2.05 (297) 11.45  1.73 (216) 11.05  1
SV by 2DE (mL) 70.42  27.21 (185) 72.64  27.04 (171) 70.36  24.48 (168) 58.93  21.10 (122) 74.36  2
Doppler SV (mL) 75.77  23.49 (349) 74.96  20.16 (307) 74.89  19.90 (335) 63.35  19.71 (256) 77.93  2
LV mass (gm) 226.07  72.54 (333) 227.45  65.02 (304) 226.78  72.98 (291) 215.08  59.02 (212) 221.19  6
LV mass index (gm/m2) 122.45  35.73 (333) 123.54  33.55 (304) 122.82  35.97 (291) 116.43  28.94 (212) 119.45  3
 Moderate AR (%) 5.2% (20/385) 6.1% (21/346) 9.1% (33/363) 1.0% (3/306) 10.0% (treatment and outcomes. Echocardiography measurements including
AV gradient were performed according to established guidelines and
LV mass was calculated using the formula of Devereaux et al: 0.83 x
([(LVEDD þ LVPWT þ IVS)3 – [(LVEDD)3]) þ0.6. LVEDD¼LV end-dia-
stolic dimension, PWT¼posterior wall thickness, and
IVST¼interventricular septal thickness.
RESULTS Echo data were available in 389 TAVR and 353 SAVR pa-
tients (Table). LVEDD, PWT, IVS, LV mass, and SV were similar in
TAVR and SAVR at baseline. These variables were unchanged at
discharge with TAVR. However, after SAVR at discharge, LV mass
decreased from 227.4565.02 to 215.0859.02 gm (P¼0.002), and
LVEDD from 5.010.64 to 4.810.65 cm (P<0.0001), although PWT
and IVS were unchanged. 2D derived stroke volume (SV) also declined
at discharge from 72.6427.04 mL to 58.9321.10 mL (P¼0.01) after
SAVR, but not after TAVR (70.4227.21 mL to 70.3624.48 mL;
P¼0.46). Similar changes were observed with Doppler derived SV. At 1
year, LV mass, SV and LVEDD remained smaller following SAVR vs.
TAVR, a difference that persisted after exclusion of those with 
moderate aortic regurgitation (AR).
CONCLUSIONS Greater LV mass regression after SAVR is due to
smaller post-operative LVEDD associated with lower SV after SAVR
than TAVR. Further study is needed to identify the reasons for
reduced SV after SAVR.
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BACKGROUND This is the ﬁrst study comparing outcomes after
transfemoral transcatheter aortic valve replacement (TAVR) with
Symetis ACURATE (ACT) - a new device -, Medtronic CoreValve (MCV)
and Edwards Sapien XT (SXT).
METHODS We prospectively evaluated patients with severe aortic
stenosis undergoing transfemoral TAVR at two centers coordinated by
the same Heart Team. Study objectives were echocardiography ﬁnd-
ings and Valve Academic Research Consortium (VARC) at 30 days.
RESULTS We evaluated 162 patients (ACT n¼48, MCV n¼57, SXT
n¼57). Baseline clinical and imaging features are resumed in Table 1.
Immediately after the procedure, Device Success were lower with
MCV (97.9% vs 86% vs 94.7%; p¼0,049), as well as Aortic Valve Area
(1.900.26 vs 1.810.32 vs 2.010.28; p¼0.002), with no differences in
Mean Gradient (p¼0.752) or Moderate/Severe Aortic Regurgitation
(p¼0.272). At 30 days, there were no signiﬁcant difference in all-cause
mortality (p¼0.298), cardiovascular mortality (p¼0.222), myocardial
infarction (p¼0.776) and stroke (p¼0.999). Additionally, no differ-
ences were found in major vascular complications (p¼0.594), life-
threatening bleeding (0.378) and stage 3 acute kidney injury1 Month 6 Months 1 Year
VR SAVR TAVR SAVR TAVR SAVR
.65 (318) 4.74  0.66 (247) 5.01  0.67 (279) 4.74  0.63 (206) 4.98  0.66 (262) 4.80  0.56 (190)
.12 (312) 11.68  2.09 (245) 11.50  2.32 (269) 11.62  1.97 (205) 11.35  2.17 (257) 11.48  2.37 (189)
.83 (307) 10.96  1.79 (237) 10.57  1.82 (266) 11.12  1.87 (199) 10.51  1.89 (255) 10.21  1.96 (189)
4.59 (173) 59.76  20.71 (123) 72.37  22.04 (141) 66.34  22.74 (100) 73.45  23.81 (118) 71.45  22.01 (81)
3.53 (349) 67.59  20.29 (282) 79.69  23.33 (297) 73.57  20.35 (224) 79.56  22.90 (278) 74.78  21.35 (206)
9.63 (303) 200.22  58.38 (232) 213.07  65.74 (260) 201.79  57.83 (196) 207.83  64.02 (247) 192.71  58.54 (185)
3.88 (303) 108.83  29.31 (232) 114.23  30.74 (260) 108.67  26.81 (196) 111.35  29.85 (247) 102.80  27.99 (185)
36/359) 1.3% (4/308) 11.3% (36/318) 1.6% (4/252) 7.1% (21/297) 1.3% (3/223)
